As biotech deals slow, Catalio Capital amasses war chest

Valuations of public biotechnology companies have taken a hit, which is expected to depress valuations and dealmaking for privately held biotechs.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this